Life sciences company Bio-Techne Corporation (NASDAQ: TECH) announced on Wednesday that its board of directors has approved a quarterly dividend of USD0.08 per share for Q3 2024.
This dividend is payable on 22 November 2024 to shareholders of record as of 11 November 2024.
The company said its board will continue to evaluate cash dividends on a quarterly basis.
Bio-Techne provides essential tools and reagents for research and clinical diagnostics, supporting drug discovery and accurate clinical testing. In fiscal 2024, the company reported USD1.2bn in net sales and employs approximately 3,100 people worldwide.
Neogap Therapeutics partners with NorthX Biologics to enhance cancer cell therapy production
Medivir partners with Eisai to evaluate fostrox in liver cancer
OSE Immunotherapeutics' Lusvertikimab shows promise in ulcerative colitis
Cytoki Pharma doses first patient with CK-0045 in Phase two proof-of-concept trial
Amphix Bio receives USD1m SBIR Phase II grant from National Science Foundation
Bexion Pharmaceuticals reports release of first-in-human data from Phase 1 study of BXQ-350
Eisai completes rolling BLA submission for lecanemab-irmb to FDA
Boehringer Ingelheim discontinues development of NYP2 agonist